Pee instead of swab: new study tests urine HPV test for cervical cancer
NCT ID NCT06254846
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a simple urine sample can be used instead of a cervical swab to screen for HPV, the virus that causes most cervical cancers. The researchers will collect first-void urine from 350 women aged 30–65 using a special device and compare the results to the standard swab test. They will also ask participants how acceptable they found the urine collection method.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- First-void urine sample collected with Colli-Pee® device
- What this could lead to
- If successful, this could offer a simple, painless urine test for HPV, making cervical cancer screening more accessible and comfortable.
- What could go wrong
- This is a single-center study with 350 participants. Previous urine tests have shown lower sensitivity, and this study is still recruiting, so results are not yet confirmed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 350 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2024
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
30 to 65 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Female * Age between 30 and 65 * Consulting in the Gynecology-Obstetrics department for primary cervical cancer screening * Patient affiliated or entitled to a social security regimen * Patient who has received information about the study and expressed non-opposition Exclusion Criteria: \-
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Uterine cervical cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Service de Gynécologie Obstétrique - CHU Saint-Etienne
RECRUITINGSaint-Etienne, 42055, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug YH32364 targets Hard-to-Treat cancers in first human trial
- Could a common painkiller combo ease cancer treatment pain?
- Promising combo for cervical cancer hits roadblock: trial ends early
- Can a simple blood test predict cancer return? new study investigates
- New blood test could replace scans for HPV cancer patients